During the last session, Emergent Biosolutions Inc (NYSE:EBS)’s traded shares were 1.28 million, with the beta value of the company hitting 1.57. At the end of the trading day, the stock’s price was $9.40, reflecting an intraday gain of 5.86% or $0.52. The 52-week high for the EBS share is $15.10, that puts it down -60.64 from that peak though still a striking 84.89% gain since the share price plummeted to a 52-week low of $1.42. The company’s market capitalization is $509.34M, and the average intraday trading volume over the past 10 days was 2.25 million shares, and the average trade volume was 2.00 million shares over the past three months.

Emergent Biosolutions Inc (EBS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.33. EBS has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.64.

Emergent Biosolutions Inc (NYSE:EBS) trade information

Emergent Biosolutions Inc (EBS) registered a 5.86% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 5.86% in intraday trading to $9.40, hitting a weekly high. The stock’s 5-day price performance is 1.40%, and it has moved by 7.43% in 30 days. Based on these gigs, the overall price performance for the year is 349.76%. The short interest in Emergent Biosolutions Inc (NYSE:EBS) is 6.95 million shares and it means that shorts have 5.21 day(s) to cover.

The consensus price target of analysts on Wall Street is $51.5, which implies an increase of 81.75% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $38 and $65 respectively. As a result, EBS is trading at a discount of -591.49% off the target high and -304.26% off the low.

Emergent Biosolutions Inc (EBS) estimates and forecasts

Statistics show that Emergent Biosolutions Inc has outperformed its competitors in share price, compared to the industry in which it operates. Emergent Biosolutions Inc (EBS) shares have gone up 90.28% during the last six months, with a year-to-date growth rate more than the industry average at 79.13% against 18.00. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 16.88% this quarter and then jump 154.24% in the quarter after that. In the rating firms’ projections, revenue will increase 5.58% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 259M as predicted by 1 analyst(s).

While earnings are projected to return 82.99% in 2024.

EBS Dividends

Emergent Biosolutions Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Emergent Biosolutions Inc (NYSE:EBS)’s Major holders

Emergent Biosolutions Inc insiders own 2.09% of total outstanding shares while institutional holders control 59.91%, with the float percentage being 61.19%. BLACKROCK INC. is the largest shareholder of the company, while 178.0 institutions own stock in it. As of 2024-06-30, the company held over 3.84 million shares (or 7.3551% of all shares), a total value of $26.18 million in shares.

The next largest institutional holding, with 3.67 million shares, is of VANGUARD GROUP INC’s that is approximately 7.0234% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $25.0 million.